1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd.

0.71
HKD
+0.00
(-0.70%)
11.12BMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.25
0.3
0.31
0.31
0.29
0.31
0.3
0.26
0.32
0.23
0.2
0.21
0.29
- -
Basic EPS, GAAP
0.12
0.16
0.2
0.17
0.15
0.17
-0.29
0.05
0.04
-0.21
-0.01
-0.02
0.02
- -
Free Cash Flow per Basic Share
0.04
0.1
0.09
0.16
0.15
0.15
0.08
-0.04
-0.01
-0.06
-0.01
0.01
-0.02
- -
Dividend per Share
0.05
0.02
0.03
0.06
0.12
0.03
0.02
0.15
0.01
0.14
0.03
0.02
0.01
- -
Book Value per Share
0.76
0.9
1.07
1.14
1.17
1.32
1.01
0.97
0.89
0.51
0.48
0.47
0.65
0.65
Tangible Book Value per Share
0.48
0.62
0.8
0.84
0.73
0.8
0.96
0.92
0.82
0.44
0.39
0.38
0.54
0.54
Basic Weighted Avg Shares
10,350
10,363
10,364
10,141
9,483
9,471
9,468
9,466
9,431
9,330
9,297
9,266
9,121
9,123
Sales/Revenue/Turnover
2,586
3,084
3,167
3,186
2,746
2,917
2,878
2,464
3,038
2,181
1,861
1,901
2,618
- -
Operating Margin (%)
57.04
61.55
64.84
58
51.61
57.26
46.93
18.22
21.32
-25.41
-10.29
-24.3
14.33
- -
Depreciation Expense
196
209
263
291
297
307
355
278
309
370
226
258
225
- -
Net Income, GAAP
1,285
1,671
2,062
1,708
1,449
1,620
-2,753
473
417
-1,915
-54
-217
180
- -
Effective Tax Rate (%)
19.39
18.74
28.04
21.96
14.47
16.54
- -
28.6
51.03
- -
- -
- -
55.56
- -
Profit Margin (%)
49.68
54.19
65.12
53.62
52.77
55.53
-95.66
19.21
13.71
-87.79
-2.9
-11.4
6.86
- -
Working Capital
3,320
3,933
4,513
4,156
2,871
3,528
4,044
3,961
5,240
4,017
2,097
2,407
2,963
2,963
LT Debt
6
4
8
- -
- -
95
15
362
876
929
957
759
735
735
Total Equity
7,937
9,406
11,192
10,971
11,336
12,774
9,942
9,949
9,150
5,640
5,137
4,949
6,900
6,900
Return on Invested Capital (%)
14.63
17.94
19.21
14.71
12.68
13.77
- -
5.43
3.6
- -
- -
- -
3.9
- -
Return on Capital (%)
15.93
18.9
20.16
15.62
12.58
12.81
- -
4.27
6.28
- -
- -
- -
3.81
- -
Return on Common Equity (%)
17.24
19.53
20.23
15.53
13.2
13.75
-24.9
5.04
4.77
-29.41
-1.18
-4.92
3.52
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
215
204
272
LT Borrowings
747
738
727
LT Finance Leases
13
19
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9,310
9,194
9,042
Market Capitalization
5,774
9,313
9,993

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
5,718
5,818
6,653
Cash, Cash Equivalents & STI
3,777
3,693
3,977
Accounts Receivable, Net
500
611
1,062
Inventories
417
472
618
Total Current Liabilities
3,310
3,327
3,690
Payables & Accruals
- -
- -
- -
ST Debt
215
204
272
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.76%
-3.91%
39.42%
Free Cash Flow
-39.04%
-50.82%
-342.92%
Net Income, GAAP
-95.85%
-110.16%
-182.94%
Sales/Revenue/Turnover
-0.24%
4.06%
37.71%
Total Cash Common Dividend
144.81%
142.47%
-48.67%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,861
2024
- -
- -
1,901
2025
- -
- -
2,618

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.02
2025
- -
- -
0.02

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.03
2024
- -
- -
0.02
2025
- -
- -
0.01

Company Description

Company Profile APIChatGPT
CEO
Wei Cheng Guo
Full Time Employees
2,843
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Office Tower, Convention Plaza Beijing China
IPO Date
Oct 28, 2010
Website
sihuanpharm.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) is an investment holding company engaged in the research, development, manufacture, and sale of pharmaceutical products with a focus on cardio-cerebral vascular, central nervous system, metabolism, oncology, diabetes, and anti-infectives therapeutic areas; it also operates in medical aesthetics and innovative biopharmaceuticals. Founded in 2001 and headquartered in Wan Chai, Hong Kong, the company maintains integrated production, R&D, and marketing capabilities supported by approximately 600 R&D personnel and an extensive nationwide distribution network in China. Its core products encompass branded generics and innovative drugs such as cinepazet maleate injection (Kelinao) for acute ischemic stroke, cardio-cerebral vascular treatments including stroke product lines, oncology drugs like CDK4/6 inhibitors in clinical trials, metabolism and diabetes therapies including metformin hydrochloride tablets that passed consistency evaluation, central nervous system offerings like gabapentin capsules, anti-infectives such as azithromycin and plazomicin, and medical aesthetics products under Meiyan Space featuring over 40 items including botulinum toxin Letybo and hyaluronic acid Persnica; the pipeline includes more than 60 innovative biopharmaceuticals and generic pharmaceuticals across small molecule, large molecule, monoclonal antibodies, bispecific antibodies, and ADCs targeting oncology, digestive diseases, and NASH. In recent developments, subsidiaries acquired additional equity stakes totaling approximately 6.99% in Xuanzhu Biopharm for RMB596 million between October and November 2024 to bolster control ahead of a proposed spin-off and Main Board listing on the Hong Kong Stock Exchange; the company signed a global cooperation agreement with U.S.-based Abalone Bio in October 2025 for a new-generation GPCR-targeted innovative therapy for weight loss and muscle gain, building on an earlier strategic investment; it completed strategic funding in Suisselle SA in September 2025 and advanced partnerships such as with South Korea's Cellontech for collagen injectables, while securing NMPA approvals for 13 generic products including dopamine hydrochloride injection in 2024 and initiating Phase II trials for pirotinib. The group primarily serves the Chinese prescription drug market with expansion into international R&D collaborations and operates through subsidiaries like Hainan Sihuan and Xuanzhu Biopharm, emphasizing a two-wheel drive strategy in medical aesthetics and biopharmaceuticals.